Collecting samples and studying the natural history of malignant mesothelioma
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma and Other Mesothelin Expressing Cancers
This study is collecting tissue samples from people with malignant mesothelioma and certain other cancers to learn more about the disease and help improve future treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 2 Years and up |
| Sex | All |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 1 site (Bethesda, Maryland) |
| Trial ID | NCT01950572 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with malignant mesothelioma and other cancers that express mesothelin. It aims to acquire tissue samples to better understand the disease's natural history and improve future treatment options. Eligible participants include individuals aged 2 years and older with confirmed diagnoses of malignant mesothelioma or other specified cancers. The study will not involve any specific interventions but will gather valuable data through sample collection.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 2 years and older with a confirmed diagnosis of malignant mesothelioma or other specified cancers.
Not a fit: Patients with active major organ disorders or those who are pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of malignant mesothelioma and lead to improved treatment strategies for patients.
How similar studies have performed: Other studies focusing on tissue procurement and natural history in similar cancers have shown promise, indicating potential for valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: * All participants greater than or equal to 2 years of age with malignant mesothelioma. * All participants greater than or equal to18 years of age with thymic carcinoma, pancreatic or biliary adenocarcinoma or lung, gastric or ovarian cancers. * Confirmed pathological diagnosis is required * Ability and willingness of participant to provide informed consent to participation. EXCLUSION CRITERIA: * Active symptomatic major organ disorder that would increase the risk of biopsy, including but not limited to ischemic heart disease, recent myocardial infarction, active congestive heart failure, pulmonary dysfunction. * Pregnant women * Active concomitant medical or psychological illnesses that may increase the risk to the participant or in adult participants, inability to obtain informed consent, at the discretion of the principal investigator.
Where this trial is running
Bethesda, Maryland
- National Institutes of Health Clinical Center — Bethesda, Maryland, United States (Recruiting)
Study contacts
- Principal investigator: Raffit Hassan, M.D. — National Cancer Institute (NCI)
- Study coordinator: Maria Gracia L Agra, R.N.
- Email: mariagracia.agra@nih.gov
- Phone: (240) 858-3152
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.